- Home
- FUFU vs CVAC Comparison
FUFU vs CVAC Comparison
Compare FUFU & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUFU
- CVAC
- Stock Information
- Founded
- FUFU 2020
- CVAC 2000
- Country
- FUFU Singapore
- CVAC Germany
- Employees
- FUFU N/A
- CVAC N/A
- Industry
- FUFU
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- FUFU
- CVAC Health Care
- Exchange
- FUFU NYSE
- CVAC Nasdaq
- Market Cap
- FUFU 737.9M
- CVAC 818.8M
- IPO Year
- FUFU N/A
- CVAC 2020
- Fundamental
- Price
- FUFU $3.35
- CVAC $3.47
- Analyst Decision
- FUFU Strong Buy
- CVAC Strong Buy
- Analyst Count
- FUFU 1
- CVAC 2
- Target Price
- FUFU $7.00
- CVAC $14.00
- AVG Volume (30 Days)
- FUFU 277.9K
- CVAC 564.4K
- Earning Date
- FUFU 05-19-2025
- CVAC 04-10-2025
- Dividend Yield
- FUFU N/A
- CVAC N/A
- EPS Growth
- FUFU 371.66
- CVAC N/A
- EPS
- FUFU 0.33
- CVAC 0.75
- Revenue
- FUFU $463,330,000.00
- CVAC $554,073,921.00
- Revenue This Year
- FUFU $5.51
- CVAC N/A
- Revenue Next Year
- FUFU $60.82
- CVAC $38.07
- P/E Ratio
- FUFU $10.27
- CVAC $4.64
- Revenue Growth
- FUFU 63.08
- CVAC 895.54
- 52 Week Low
- FUFU $2.32
- CVAC $2.22
- 52 Week High
- FUFU $7.39
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- FUFU 35.18
- CVAC 59.19
- Support Level
- FUFU $3.15
- CVAC $3.38
- Resistance Level
- FUFU $3.61
- CVAC $3.79
- Average True Range (ATR)
- FUFU 0.40
- CVAC 0.20
- MACD
- FUFU -0.07
- CVAC 0.04
- Stochastic Oscillator
- FUFU 11.91
- CVAC 57.35
About FUFU BITFUFU INC
BitFuFu Inc is a digital asset mining and cloud-mining service provider that fosters a secure, compliant, and transparent blockchain infrastructure. It provides stable and intelligent digital asset mining solutions, including one-stop cloud-mining services and miner hosting services to institutional customers and individual digital assets.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.